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dehydrogenase complex, and the glycine cleavage system. As an antioxidant, LA can be reduced to its redox partner, DHLA, which is a powerful reducing agent and important in the regeneration of endogenous antioxidants such as glutathione. Importantly, LA can act as a metal chelator, a scavenger of ROS, and is able to repair damage from oxidative stress. This antioxidant effect and role of LA in carbohydrate metabolism has made it a very appealing potential drug in diseases such as diabetic neuropathy, MS, and Alzheimer's disease, where oxidative damage is presumed to play a pathogenic role. 8, 9 Multiple Sclerosis Is an Inflammatory Disease of the
Central Nervous System
Inflammation due to a dysregulated immune system plays a pivotal role in MS pathogenesis. The etiology of this inflammatory response is unknown, but once activated the T and B cells, macrophages, adhesion molecules, and soluble mediators of inflammation such as cytokines play significant roles in causation and propagation of the disease.
Matrix Metalloproteinase-9, Adhesion Molecules, and

Cytokines in Multiple Sclerosis
The transmigration of activated immune cells across the BBB plays a significant role in MS pathogenesis as it leads to the development of new inflammatory lesions in MS. 16 MMPs are also produced by these activated pro-inflammatory T cells, particularly MMP-9, which enzymatically disrupt the subendothelial membrane and extracellular matrix components, allowing the ingress of T cells into the CNS parenchyma. [17] [18] [19] [20] [21] Clinical trials have suggested that serum mean MMP-9 levels are increased in MS patients with clinical and magnetic resonance imaging (MRI) disease activity and that a shift in MMP-9/TIMP-1 balance toward proteolytic activity of MMP-9 could be relevant in MS immune dysregulation, 22 whereas the MMP-9/TIMP-1 ratio in serum showed higher (p=0.04) values in stable relapsing-remitting MS (RRMS) than primary progressive (PP) but also in active patients, evaluated either clinically (p=0.006) or from the MRI (p<0.05), compared with inactive disease. 23 In addition, increased serum levels of sICAM-1 have been associated with inflammatory disease activity and with the appearance of gadolinium enhancing lesions on brain MRI. [24] [25] [26] Studies have shown that upregulated adhesion molecules in blood and serum could indicate ongoing inflammation in the CNS in MS subjects. 27, 28 The role of cytokines in MS pathogenesis is evident by correlations that exist between expression of pro-inflammatory cytokines during periods of clinical worsening and of regulatory cytokines during periods of clinical remission. 
Macrophages and Oxidative Injury in Multiple Sclerosis
In addition to the role of T and B cells in MS pathogenesis, activated macrophages and microglia also play a significant role in tissue destruction as well as repair. 37 Macrophages produce pro-inflammatory enzymes such as proteases, lipases, and cytokines and special molecules such as osteopontin that destroy tissues in a variety of ways. In addition, macrophages are a source of reactive oxygen and nitrogen species, thus causing oxidative damage.
Therapeutic agents that target adhesion molecules and MMP-9 may prove useful as treatments for MS and other neurological diseases in which migration of inflammatory cells plays a pathogenic role. [38] [39] [40] [41] [42] [43] A growing body of literature exists that demonstrates the ability of LA to reduce the expression of surface adhesion molecules on endothelial cells, suppress MMP-9 activity, and inhibit the trafficking of inflammatory cells across the BBB. 5, 6, [44] [45] [46] Taken together, these data provide evidence for the further evaluation of LA as a therapeutic agent in MS.
Animal Model of Multiple SclerosisExperimental Autoimmune Encephalomyelitis
As a widely used model of MS, experimental autoimmune encephalomyelitis (EAE) has provided important insights into the immunopathogenesis of MS and led to the development of new therapeutic LA inhibits MMP-9 activity directly and at the level of transcription. Subjects who took 1,200mg LA had substantially higher C max levels (range 0-19µg/ml) than those taking 600mg LA (range 0-3.7µg/ml).
Authors also explored the effects of LA C max on the levels of serum MMP-9. The baseline MMP-9 levels were obtained prior to patients receiving the study drug. Subsequent MMP-9 levels were measured at three additional time-points. These included 24 hours after the study initiation (visit three of study), at one week (visit four of study), and at the end of two weeks (visit five) of the study. The outcome measure was the mean change in MMP-9 levels compared with baseline and visits three, four, and five. A significant negative correlation between the LA C max values and the MMP-9 mean change (Kendall's tau=0.263; p≤0.04) was observed.
The outcome measure was to evaluate the relationship between LA and serum sICAM-1 levels with the mean change between visits three, four, and five compared with baseline sICAM-1. Those subjects who took higher doses of LA showed the greatest decrease in sICAM-1 (Jonckheere-Terpstra test; p=0.03), suggesting a significant dose-response relationship between LA dose and the mean change in sICAM-1.
Safety data revealed that high-dose LA was generally safe and well tolerated. Nausea, mild gastrointestinal discomfort, and strange odor in the urine were minor complaints of some subjects in the study. One subject developed a reversible disseminated maculopapular allergic rash with fever that required discontinuation of LA.
Further studies to better understand the mechanism of action of lipoic acid are under way. Further studies to better understand the mechanism of action of LA are under way. The use of oral LA as a potential treatment for MS will be a major breakthrough in MS therapeutics. ■
